In order to study preclinical predictors of the development of Alzheimer's disease (AD), 165 subjects were evaluated and then followed for an average of 3 years. The baseline evaluation included medical, neurologic and psychiatric evaluations, standardized laboratory tests, and a semistructured interview. On the basis of this examination, 123 individuals met criteria for ''questionable'' AD, according to the Clinical Dementia Rating (CDR) scale (i.e., CDR ϭ 0.5), and 42 individuals met criteria for controls (CDR ϭ 0.0). Participants then received a neuropsychological test battery, genotyping for the apolipoprotein E gene (APOE) and a variety of neuroimaging procedures, including single photon emission tomography (SPECT), and structural magnetic resonance imaging. Annual evaluations were then given to determine which individuals experienced progressive cognitive decline over time, to the point where they met NINCDS/ADRDA criteria for AD. The data were then examined to identify which measures gathered at baseline best predicted ''conversion'' to AD on follow-up.
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In order to study preclinical predictors of the development of Alzheimer's disease (AD), 165 subjects were evaluated and then followed for an average of 3 years. The baseline evaluation included medical, neurologic and psychiatric evaluations, standardized laboratory tests, and a semistructured interview. On the basis of this examination, 123 individuals met criteria for ''questionable'' AD, according to the Clinical Dementia Rating (CDR) scale (i.e., CDR ϭ 0.5), and 42 individuals met criteria for controls (CDR ϭ 0.0). Participants then received a neuropsychological test battery, genotyping for the apolipoprotein E gene (APOE) and a variety of neuroimaging procedures, including single photon emission tomography (SPECT), and structural magnetic resonance imaging. Annual evaluations were then given to determine which individuals experienced progressive cognitive decline over time, to the point where they met NINCDS/ADRDA criteria for AD. The data were then examined to identify which measures gathered at baseline best predicted ''conversion'' to AD on follow-up.
The neuropsychological battery administered at baseline included tests of attention, language, memory, spatial ability and executive function. The variables that best predicted conversion to AD over time derived from tests of memory and executive function (i.e., a measure of delayed recall from the California Verbal Learning test and time to completion on Trails B of the Trailmaking Test, p Ͻ .0001). These findings are consistent with previous reports that delayed recall and executive function measures are useful in differentiating mildly impaired AD patients from controls.
Information about the subject's APOE genotype made a modest, but significant, contribution to the accuracy of prediction. As in numerous other studies, the APOE-4 genotype was more likely to be present among ''converters.''
